Research Paper Volume 15, Issue 18 pp 9779—9796
Pan-cancer analysis and experimental validation identify ndc1 as a potential immunological, prognostic and therapeutic biomarker in pancreatic cancer
Figure 7. Correlation between NDC1 expression and IC50 of multiple anti-tumor drugs, including Chelerythrine, Allopurinol, 8-Chloro-adenosine, PX-316, Nelarabine, Parthenolide, 7-Tert-butyldimethylsilyl-10-hydroxycamptothecin and Elliptinium Acetate.